Pole des neurosciences, B4 Neurology unit, CHU de Purpan, Toulouse, France.
Pole des neurosciences, B4 Neurology unit, CHU de Purpan, Toulouse, France.
Rev Neurol (Paris). 2018 Jun;174(6):419-428. doi: 10.1016/j.neurol.2018.03.012. Epub 2018 Apr 25.
Today, first-line treatments for multiple sclerosis include injectable immunomodulators - some of which have been on the market for nearly 25 years - as well as teriflunomide and dimethyl fumarate, which are more recent, but have opened the way for oral treatments. These drugs are considered similar in effectiveness, and their safety and side-effect profiles are generally reassuring. These treatments have been associated with a reduction in radiological and clinical disease activity, and a positive effect on patient quality of life, especially when introduced early in the disease process. This article will discuss data on first-line treatments currently available in France, their effectiveness and safety, and their place in pediatric patients and in woman who plan to become pregnant.
目前，多发性硬化症的一线治疗方法包括注射用免疫调节剂——其中一些药物已经上市近 25 年——以及特立氟胺和富马酸二甲酯，它们是更新的药物，但为口服治疗开辟了道路。这些药物在疗效上被认为是相似的，它们的安全性和副作用概况通常是令人放心的。这些治疗方法与放射学和临床疾病活动的减少以及对患者生活质量的积极影响有关，特别是在疾病早期引入时。本文将讨论法国目前可用的一线治疗药物的数据、它们的疗效和安全性，以及它们在儿科患者和计划怀孕的女性中的地位。
